Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors

Please visit answersincme.com/XRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses how to optimize the use of adjuvant CDK4/6 inhibitors for managing patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. A patient also shares their experience with adjuvant CDK4/6 inhibitor therapy. Upon completion of this activity, participants should be better able to: Identify patients with hormone receptor–positive, HER2-negative, early breast cancer who are at a high risk of recurrence; Review current guidelines and evidence informing the use of adjuvant CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer; and Outline patient-centered strategies to optimize outcomes with adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative, high-risk early breast cancer.

There are no comments yet.

Please log in to write the first comment.